For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it

Sponsorship complete. Dine on...

Nutrition, wellness, weight loss, and calmer healthy living.

Obesity Medications Show Weight Loss Benefits but Limited Quality of Life Improvements

Jul 14, 2026
Obesity Medications Show Weight Loss Benefits but Limited Quality of Life Improvements

Obesity is recognized as a significant global health challenge, with the World Health Organization (WHO) declaring it a global epidemic. In response, there is a growing demand for weight-loss medications, particularly GLP-1 drugs such as Wegovy, Zepbound, and Foundayo, all of which have received approval from the Food and Drug Administration (FDA) for this purpose. A survey conducted by the Kaiser Family Foundation (KFF) indicates that approximately 12% of adults in the United States have used a GLP-1 drug, with the figure rising to around 22% among those diagnosed with overweight or obesity.

Despite the ability of these medications to facilitate clinically meaningful weight loss when combined with lifestyle changes, new research published in The BMJ suggests that the anticipated benefits may not extend to significant improvements in quality of life or cardiovascular health for many users. The analysis reviewed evidence from 262 randomized controlled trials involving nearly 100,000 participants, with a median age of 49 and a median body mass index (BMI) of 35, predominantly female (63%).

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it

Sponsorship complete. Dine on...

The review examined 19 current and emerging obesity medications, assessing various outcomes, including weight loss, body fat changes, quality of life, side effects, and cardiovascular outcomes. While the trials demonstrated that obesity drugs could lead to substantial weight loss, the findings revealed that only a few medications showed evidence of improving heart-related outcomes after one year of treatment. This underscores the necessity of tailoring obesity treatment decisions to individual patient needs, considering expected benefits, potential harms, treatment burden, costs, availability, and personal preferences.

Researchers noted a consistent trend: greater weight loss was often accompanied by a higher incidence of side effects and treatment discontinuation. For instance, tirzepatide was associated with the most significant fat mass reduction, yet it also resulted in the largest loss of lean mass. The study emphasizes that obesity drugs should not be evaluated solely on weight loss metrics. According to study author Sheyu Li, PhD, a clinical professor and endocrinologist, treatment decisions should be individualized, factoring in cardiovascular prevention for high-risk patients, the loss of fat versus lean mass, and the discomfort caused by the drugs.

Despite some medications showing effectiveness in weight loss, most did not yield clear enhancements in quality of life. Notably, injectable semaglutide was linked to a lower risk of major cardiovascular events, including a 19% reduction in all-cause mortality and a 28% reduction in heart attack risk. In contrast, the average effect on quality of life was found to be neutralized for many patients, particularly those at lower cardiovascular risk.

The study authors pointed out that many trials had relatively short follow-up periods, complicating the assessment of long-term safety and quality of life impacts. They also highlighted that evidence for newer treatments remains limited, and trial participants may not fully represent the broader population using these medications. The findings aim to assist healthcare professionals and patients in discussing the potential pros and cons of various obesity treatment options.

Li concluded that treatment goals should encompass more than just weight loss, extending to overall well-being, physical function, and the prevention of obesity-related complications. He stressed the importance of shared decision-making between clinicians and patients, focusing on what matters most to the individual rather than presenting a single medication as the best option. Mir Ali, MD, a bariatric surgeon, echoed this sentiment, noting that while weight loss is beneficial, it does not guarantee improvements in all health conditions or aspects of life. He emphasized that successful long-term weight control requires meaningful lifestyle changes in conjunction with medication use.

In summary, while obesity medications can facilitate weight loss, their impact on quality of life and cardiovascular health remains limited for many patients. The decision to use these medications should be personalized, taking into account individual health priorities and the potential for both benefits and side effects.

For Your Kitchen
Cookbooks
Taste it
Kitchen Scales
Taste it
Meal Prep Containers
Taste it
Vegetable Prep & Salad Spinners
Taste it

Sponsorship complete. Dine on...

For Your Kitchen
Cookbooks

Everyday recipes with room for flavor, variety, and real life. Dinner should not feel like homework.

Taste it
Kitchen Scales

Kitchen scales for recipes that deserve more precision than 'that looks about right.'

Taste it
Meal Prep Containers

Give tomorrow's lunch a proper home. Containers for meals worth looking forward to.

Taste it
Vegetable Prep & Salad Spinners

Salad spinners and vegetable-prep tools for everyday salads, bowls, and side dishes. A little less kitchen setup, a little more time to enjoy the meal.

Taste it
Blenders & Smoothie Tools

Blenders for fruit, yogurt, soups, and the combinations you actually enjoy. Everyday kitchen tools, not a promise in a glass.

Taste it
Sheet Pans & Roasting Essentials

Sheet pans and roasting racks for vegetables and simple oven meals. Useful equipment for dinner without an elaborate production.

Taste it

Sponsorship complete. Dine on...

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)